By signing in or creating an account, you agree with Associated Broadcasting Company's Terms & Conditions and Privacy Policy.
Kolkata: Gujarat Kidney IPO is a significant issue that is going to be the last mainboard public issue to list in 2025. This is a year with 104 listings and about 270 SME IPOs. Therefore, Gujarat Kidney issue will remain as the last IPO of a record year. Moreover, a lot of retail investors will be eager to know the debut price of the shares. However, there seems to be an interesting dissonance between the GMP and the level of application by retail investors.
According to investorgain, Gujarat Kidney IPO GMP stood at Rs 1.50 in the morning of Dec 30. In fact, it has been able to crawl up from the level of zero to Rs 1.50 only on Dec 30, show investorgain data. The GMP was Rs 10 on Dec 18 and then began crawling down on the following days till it reached zero on Dec 24. Therefore, the debuted is expected to happen at the price of Rs 115.50 and the listing gain could be 1.32%. However, it must be kept in mind that GMP is an unofficial indicator that is volatile and cannot guarantee anything -- listing gain or loss.
Gujarat Kidney IPO was subscribed 5.21 times overall -- 19.04 times in the retail category, 1.06 times in QIB (Ex Anchor) category and 5.73 times in the NII category. From the above figure it is clear that retail investors were enthusiastic about this public issue. However, QIBs were not as enthusiastic as the retail investors. QIB, or Qualified Institutional Buyers, are usually banks, insurance firms and AMCs which have the deep pockets to invest big amounts and the professional skills to analyse an IPO threadbare.
Gujarat Kidney and Super Speciality was set up in 2019. The company provides multispeciality healthcare services, including secondary and tertiary care, across multiple locations in Gujarat. There are seven multispeciality hospitals and four pharmacies under this company and the total bed capacity is 490 beds. The hospitals are in Vadodara, Godhra, Bharuch, Borsad and Anand.
(Disclaimer: This article is only meant to provide information. TV9 does not recommend buying or selling shares or subscriptions of any IPO, Mutual Funds, precious metals, commodity, REITs, InvITs and any form of alternative investment instruments and crypto assets.)